Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
367 studies found for:    "Squamous cell carcinoma of the head and neck"
Show Display Options
Rank Status Study
1 Not yet recruiting PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Conditions: Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma
Interventions: Drug: Pembrolizumab;   Radiation: Radiotherapy;   Drug: Chemotherapy
2 Terminated EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
3 Completed
Has Results
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab;   Drug: EMD 1201081
4 Unknown  E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Condition: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: E7050;   Drug: Cetuximab
5 Completed Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
6 Recruiting Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Plasma samples
7 Completed Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Bevacizumab;   Drug: erlotinib;   Drug: Sulindac
8 Active, not recruiting Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Erlotinib chlorhydrate;   Drug: Cisplatin;   Procedure: Radiation therapy
9 Terminated Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus;   Drug: cisplatin;   Drug: cetuximab
10 Completed Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: dacomitinib;   Radiation: Radiotherapy;   Drug: Cisplatin
11 Unknown  MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Biological: MAGE-A3;   Biological: HPV-16 vaccine
12 Active, not recruiting Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Cetuximab and stereotactic radiosurgery
13 Completed Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cabazitaxel;   Drug: Methotrexate
14 Terminated
Has Results
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: AT-101;   Drug: Docetaxel
15 Completed
Has Results
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Cetuximab + concomitant boost radiotherapy
16 Completed
Has Results
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Drug: Cisplatin/Carboplatin;   Drug: 5-Fluorouracil
17 Recruiting Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Conditions: Squamous Cell Carcinoma of the Head and Neck;   Carcinoma, Squamous Cell of the Head and Neck;   Cancer of Head and Neck;   Cancer of the Head and Neck;   Head and Neck Cancer;   Neoplasms, Head and Neck
Interventions: Drug: nab-Paclitaxel;   Drug: Cisplatin;   Biological: Cetuximab;   Radiation: Intensity-Modulated Radiation Therapy
18 Withdrawn Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Condition: Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Interventions: Drug: sorafenib;   Drug: sorafenib and cisplatin
19 Completed A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
20 Active, not recruiting Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Intervention: Drug: MEDI4736

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years